Healthcare PharmaceuticalsPrescription oral medication for relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS. Developed and marketed by Novartis. FDA-approved in 2010 as the first oral disease-modifying therapy for MS. Generic fingolimod entered the US market in 2024 after patent expiration.
immunologymultiple-sclerosisprescription